We hope to see you again soon!
You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
Pipeline
Therapies in development
Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest unmet need.
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Lu AF28996 (D1-D2 agonist) | Neurology | 1 | ||||
| Lu-AF41156 (D2 agonist) | Psychiatry | 2 | ||||
| Lu AG06466 (MAGL inhibitor) | Psychiatry + Neurology | 1 | ||||
| Lu AG09222 (anti-PACAP mAb) | Neurology | 2 |
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Lu AF28996 (D1-D2 agonist) | Neurology | 1 | ||||
| Lu-AF41156 (D2 agonist) | Psychiatry | 2 | ||||
| Lu AG06466 (MAGL inhibitor) | Psychiatry + Neurology | 1 | ||||
| Lu AG09222 (anti-PACAP mAb) | Neurology | 2 |
* CD40L/serum-albumin bispecific antibody-fragment ((scFv)2-Fab)) based on AprilBio’s SAFA™ technology platform.
More from Lundbeck
Research and development
R&D of new and improved treatments is at the core of what we do.
Understanding brain diseases
The journey to brain health starts with understanding the diseases in the brain.
Our commitment
We strive for Progress in Mind - our multifaceted approach to patients.
UK-NOTPR-1886 | April 2024